The tertiary prevention of hepatocellular carcinoma in chronic hepatitis C patients (original) (raw)
Hepatitis C virus and hepatocellular carcinoma
Raffaella Romeo
Best Practice & Research Clinical Gastroenterology, 1999
View PDFchevron_right
HCV- and HCC-Ann Hepatol 2010-Fassio
Eduardo Fassio
View PDFchevron_right
Treatment with direct‐acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma
Andres Bruno
Liver International, 2019
View PDFchevron_right
Treatment efficacy for patients with chronic hepatitis C and preexisting hepatocellular carcinoma by directly acting antivirals
Hepatoma Research
Hepatoma Research, 2020
View PDFchevron_right
Varied Virological Response of Patients with Chronic Hepatitis C against the Treatment of Pegylated Interferon- α and Ribavirin
Sandeep Vishwakarma
IOSR Journal of Pharmacy (IOSRPHR), 2014
View PDFchevron_right
Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: influence of HCV genotype
angelo sangiovanni
European Journal of Gastroenterology & Hepatology, 2001
View PDFchevron_right
Eradication of Hepatitis C Virus Reduces the Risk of Hepatocellular Carcinoma in Patients with Compensated Cirrhosis
Rui Marinho
Digestive Diseases and Sciences, 2011
View PDFchevron_right
Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment
Wan-long Chuang
EBioMedicine, 2016
View PDFchevron_right
Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV‐TARGET Analysis
Lucy Akushevich
Hepatology Communications, 2019
View PDFchevron_right
Is pegylated interferon superior to interferon, with ribavarin, in chronic hepatitis C genotypes 2/3?
Maimoona Azhar
2008
View PDFchevron_right
Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments
Giota Touloumi
Journal of Viral Hepatitis, 2005
View PDFchevron_right
The introduction of direct-acting antivirals (DAAs) has revolutionized the natural history of chronic hepatitis C virus (HCV) infection, as the high rates of sustained virologic response (SVR) have been associated with improved survival in both cirrhotic and noncirrhotic
Antonio Colecchia
2019
View PDFchevron_right
Sustained Virological Response among Chronic Hepatitis C Virus Infected Patients Treated with Pegylated Interferon ( INF ) and Ribavirin ( RBV ) in Sana'a Yemen 2013
ahmed moharram
The Egyptian Journal of Medical Microbiology, 2014
View PDFchevron_right
Short versus standard treatment with Pegylated interferon alfa-2a plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the CLEO trial
Antonio Picardi
BMC Gastroenterology, 2010
View PDFchevron_right
Increased incidence or recurrence of hepatocellular carcinoma in hepatitis C virus cirrhotic patients treated with direct-acting antivirals: myth or fact?
Giuseppe Cabibbo
Expert Review of Anticancer Therapy, 2018
View PDFchevron_right
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients
Wan-long Chuang
Scientific reports, 2017
View PDFchevron_right
Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study
Aurelio Sonzogni
Hepatology, 2004
View PDFchevron_right
Genotype and viral load as prognostic indicators in the treatment of hepatitis C
C. Trepo
Journal of Viral Hepatitis, 2000
View PDFchevron_right
Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients
Saeed Hamid
Alimentary Pharmacology & Therapeutics, 2010
View PDFchevron_right
Treatment of genotype 2 and 3 chronic hepatitis C virus-infected patients
Giuliano Ramadori
World Journal of Gastroenterology, 2005
View PDFchevron_right
HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma
George Ioannou
Journal of hepatology, 2017
View PDFchevron_right
On the outcome of antiviral therapy for hepatitis C virus genotype 2 or 3 infection
Åsa Alsiö
2011
View PDFchevron_right
Corrigendum to "Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment" [EBioMedicine 15 (2017) 81-89]
Wan-long Chuang
EBioMedicine, 2017
View PDFchevron_right
Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype
Susanna Naggie
Hepatology, 2010
View PDFchevron_right
Successful antiviral therapy determines a significant decrease in squamous cell carcinoma antigen-associated (SCCA) variants’ serum levels in anti-HCV positive cirrhotic patients*
Stefano Marenco
Journal of Viral Hepatitis, 2009
View PDFchevron_right